Bristol Myers Squibb

News

Gilead faces lawsuit over HIV drug pricing

Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.

News

Celgene-BMS merger looks good to go as shareholder backs dow...

Bristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out of a campaign against the $74 billion deal.

News

Celgene gets US patent let-off ahead of BMS merger

Shares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on its multi-billion dollar cancer drug Revlimid, a decision that could ease shareholder ten

Views & Analysis

Oncology round-up: Shareholders question BMS/Celgene merger,...

Will it happen or not?

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Keytruda could get patient-friendly 6 week dosing schedule i...

US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pemb

News

Largest BMS shareholder opposes Celgene deal

Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt.

Gilead faces lawsuit over HIV drug pricing

Celgene-BMS merger looks good to go as shareholder backs dow...

Celgene gets US patent let-off ahead of BMS merger

Oncology round-up: Shareholders question BMS/Celgene merger,...

Keytruda could get patient-friendly 6 week dosing schedule i...

Largest BMS shareholder opposes Celgene deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks